(Adds analyst comments in paragraphs 4, 6-7) Sept 18 (Reuters) – Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
CHINA'S VICE PREMIER HE LIFENG WILL LEAD TRADE DELEGATION TO US SEPT 19-23 - MOFCOM…
By Jeffrey Dastin and Michael Erman SAN FRANCISCO, Sept 18 (Reuters) - Anthropic has quietly…
By Echo Wang, Krystal Hu and Milana Vinn Sept 18 (Reuters) - Anthropic is considering…
St. Louis City will look to continue their ascent up the Western Conference table when…
WASHINGTON, Sept 18 (Reuters) - The U.S. State Department approved a near $2.7 billion military…
By Jody Godoy Sept 18 (Reuters) - Paramount and states seeking to block its $110…